Skip to content

Janux Therapeutics JANX Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$24.36M+23.7%-$31.95M-31.4%-$24.31M+28.2%-$33.86M-44.0%-$23.51M-16.3%
$469K+0.2%$468K-6.6%$501K-7.4%$541K+4.2%$519K+1.4%
$9.27M-2.6%$9.52M+5.2%$9.04M-17.5%$10.96M+2.4%$10.7M+71.2%
$35M$0$0
-$1.61M-197%$1.67M+1,093%-$168K-115%$1.11M+168%-$1.64M-205%
-$2.03M$6.18M+114%$2.89M+66.8%$1.73M
$1.34M+7,132%-$19K+71.2%-$66K+33.3%-$99K-7.6%-$92K-251%
$46.27M$0$0$0$0
-$12.34M+56.8%-$28.54M-122%-$12.86M+46.0%-$23.81M-39.9%-$17.02M-1.8%
$273K+158%$106K+14.0%$93K-80.3%$473K+27.5%$371K+783%
$112.75M-8.5%$123.28M+4.5%$117.97M+27.3%$92.69M-75.0%$371.29M+1,445%
$121.31M-20.7%$152.93M+21.0%$126.37M+33.4%$94.72M+203%$31.27M-46.1%
$8.29M-$340.39M
$3.55M$901K
$3.55M+20.4%$2.94M+497%$493K-48.3%$954K+72.2%$554K-99.9%
-$506K$0+100%-$4.06M+81.0%-$21.3M+94.0%-$356.86M-188%
$2.62M-25.5%$3.52M-23.8%$4.62M-11.2%$5.21M+23.3%$4.22M+44.2%
$469K+0.2%$468K-6.6%$501K-7.4%$541K+4.2%$519K+1.4%
$46.27M$0$0$0$0
$36K$6K+20.0%$5K
$1.34M+492%$227K$349K-50.1%$700K+245%
$121.31M-20.7%$152.93M+21.0%$126.37M+33.4%$94.72M+203%$31.27M-46.1%
$0$347K
$25K+125%-$101K-287%$54K+128%-$190K-180%$237K
-$3.74M$815K+9,156%-$9K-101%$1.59M
$235.75K0.0%$235.75K0.0%$235.75K0.0%$235.75K
-$12.61M+56.0%-$28.65M-121%-$12.95M+46.7%-$24.29M-39.6%-$17.4M-3.7%
-$12.61M+56.0%-$28.65M-121%-$12.95M+46.7%-$24.29M-39.6%-$17.4M-3.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Janux Therapeutics generate?
Janux Therapeutics (JANX) generated -$77.5M in operating cash flow over the trailing twelve months.
What is Janux Therapeutics's free cash flow?
After $945.0K of capital expenditures, Janux Therapeutics's free cash flow was -$78.5M over the trailing twelve months, down 68.7% year over year.
Where does Janux Therapeutics's cash flow data come from?
Every line is extracted from Janux Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.